Biological
YSCH-01
YSCH-01 is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph early_phase_1
2
67%
Ph phase_1
1
33%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 12 (66.7%)
Phase 11 (33.3%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingearly_phase_1
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500
recruitingearly_phase_1
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
NCT07538128
not_yet_recruitingphase_1
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
NCT07307053
Clinical Trials (3)
Showing 3 of 3 trials
NCT07793500Early Phase 1
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07538128Early Phase 1
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
NCT07307053Phase 1
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3